The Asia Pacific Vaccine Adjuvants Market would witness market growth of 4.0% CAGR during the forecast period (2023-2030).
Mucosal vaccines possess considerable promise and merit in mitigating infections induced by various pathogens. When developing mucosal vaccines, the most formidable obstacle is identifying adjuvants and drug delivery methods that are both safe and productive. Significant advancements have been achieved in developing mucosal adjuvants through the utilization of diverse vaccine delivery systems, detoxified bacteria toxin derivatives, pathogen-related molecules, and cytokines. Moreover, specific natural substances can enhance the immune response and may be used as vaccination adjuvants. Natural product-based immune adjuvants possess several benefits compared to conventional adjuvants, including low production costs, high stability, and low toxicity.
A significant number of pathogens, including influenza viruses, human papillomavirus (HPV), HIV, and the malaria parasite, exhibit either strain variations or substantial antigenic drift. Consequently, adjuvants' capacity to expand the profile of an immune response may be critical to the efficacy of vaccines designed to combat such targets. Experimentally, massively parallel sequencing has demonstrated that increased titers and the expansion of B cell diversity may mediate adjuvants' expanding effect. Adjuvant-induced antibody response diversification in the influenza and HPV vaccines has been proven in clinical settings.
By approximately 2050, China is projected to have 487 million citizens aged 60 or older, as reported by the Office of the National Working Commission on Aging. Furthermore, the State Council of the People's Republic of China reported that the nation has increased its efforts in recent years to promote the integration of medical and geriatric care services, advance diversified long-term care services based on community and home, and conduct trials for long-term care insurance. Thus, the demand for market may experience an upward trajectory with the aging population, as greater emphasis may be placed on developing and utilizing vaccines that demonstrate enhanced efficacy among the older population.
The China market dominated the Asia Pacific Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $143.7 Million by 2030. The Japan market is registering a CAGR of 3.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 4.7% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Mucosal vaccines possess considerable promise and merit in mitigating infections induced by various pathogens. When developing mucosal vaccines, the most formidable obstacle is identifying adjuvants and drug delivery methods that are both safe and productive. Significant advancements have been achieved in developing mucosal adjuvants through the utilization of diverse vaccine delivery systems, detoxified bacteria toxin derivatives, pathogen-related molecules, and cytokines. Moreover, specific natural substances can enhance the immune response and may be used as vaccination adjuvants. Natural product-based immune adjuvants possess several benefits compared to conventional adjuvants, including low production costs, high stability, and low toxicity.
A significant number of pathogens, including influenza viruses, human papillomavirus (HPV), HIV, and the malaria parasite, exhibit either strain variations or substantial antigenic drift. Consequently, adjuvants' capacity to expand the profile of an immune response may be critical to the efficacy of vaccines designed to combat such targets. Experimentally, massively parallel sequencing has demonstrated that increased titers and the expansion of B cell diversity may mediate adjuvants' expanding effect. Adjuvant-induced antibody response diversification in the influenza and HPV vaccines has been proven in clinical settings.
By approximately 2050, China is projected to have 487 million citizens aged 60 or older, as reported by the Office of the National Working Commission on Aging. Furthermore, the State Council of the People's Republic of China reported that the nation has increased its efforts in recent years to promote the integration of medical and geriatric care services, advance diversified long-term care services based on community and home, and conduct trials for long-term care insurance. Thus, the demand for market may experience an upward trajectory with the aging population, as greater emphasis may be placed on developing and utilizing vaccines that demonstrate enhanced efficacy among the older population.
The China market dominated the Asia Pacific Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $143.7 Million by 2030. The Japan market is registering a CAGR of 3.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 4.7% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Scope of the Study
Market Segments Covered in the Report:
By Type
- Particulate
- Adjuvant Emulsion
- Pathogen
- Combination
- Others
By Administration
- Intramuscular
- Intranasal
- Oral
- Intradermal
- Others
By Application
- Infectious Diseases
- Cancer
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Vaccine Adjuvants Market, by Type
Chapter 6. Asia Pacific Vaccine Adjuvants Market, by Administration
Chapter 7. Asia Pacific Vaccine Adjuvants Market, by Application
Chapter 8. Asia Pacific Vaccine Adjuvants Market, by Country
Chapter 9. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Methodology
LOADING...
